Takeda Stock Rises After Positive Phase 3 Results for Narcolepsy Drug

Takeda Pharmaceutical Stock: An Excellent Candidate For Long-Term Investors (NYSE:TAK)

Takeda stock rises after positive Phase 3 results for narcolepsy drug

Takeda's narcolepsy programme gets back on track

Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.

Takeda to seek approval of new kind of narcolepsy drug after study data

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that targets orexin proteins.

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass. -- Takeda ( TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin-producing neurons in the brain. Orexin agonists are designed to addres…

Takeda sees positive late-stage results for oveporexton in narcolepsy